Compare Corning Incorporated (GLW) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corning Incorporated vs Medpace Holdings Inc — how do they compare? Corning Incorporated trades at $156.69 (market cap $131.65B), while Medpace Holdings Inc trades at $612.05 (market cap $16.82B). The key difference: Corning Incorporated is far larger — about 7.8× Medpace Holdings Inc's market cap, and Corning Incorporated pays a 0.73% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Corning Incorporated for 36 Days and Medpace Holdings Inc for 14 Days on average.
| GLW | MEDP | |
|---|---|---|
Market Cap | $131.65B | $16.82B |
Volume | 8,992,522 | 223,093 |
Sector | Technology | Health |
52-Week High | $255.79 | $630.19 |
52-Week Low | $78.03 | $393.42 |
Typical Hold Time | 36 Days | 14 Days |
Enterprise Value | $138.52B | $16.44B |
Dividend Yield | 0.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Corning (GLW) trades at $152.81, down 6.37% on the day amid a bearish technical signal. The stock shows strong fundamentals with revenue growth to $15.63B in 2025 and net income of $1.60B, alongside a recent $3B+ fiber supply deal with AT&T announced September 29, 2026. Analyst consensus is bullish with a $171.25 price target, though valuation ratios like a P/E of 70.43 appear elevated.
The outlook is positive given earnings beats and strategic deals, but risks include high valuation, patent litigation, and macroeconomic sensitivity. Upside hinges on execution of the AT&T contract and sustained demand for optical communications driven by AI and data growth.
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
